Zentalis Pharmaceuticals (ZNTL) Common Equity (2022 - 2025)
Historic Common Equity for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $252.9 million.
- Zentalis Pharmaceuticals' Common Equity fell 2863.34% to $252.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.9 million, marking a year-over-year decrease of 2863.34%. This contributed to the annual value of $337.2 million for FY2024, which is 2290.97% down from last year.
- Latest data reveals that Zentalis Pharmaceuticals reported Common Equity of $252.9 million as of Q3 2025, which was down 2863.34% from $274.5 million recorded in Q2 2025.
- Over the past 5 years, Zentalis Pharmaceuticals' Common Equity peaked at $523.3 million during Q2 2023, and registered a low of $252.9 million during Q3 2025.
- In the last 4 years, Zentalis Pharmaceuticals' Common Equity had a median value of $385.7 million in 2023 and averaged $389.0 million.
- As far as peak fluctuations go, Zentalis Pharmaceuticals' Common Equity surged by 2217.5% in 2023, and later plummeted by 3561.45% in 2025.
- Zentalis Pharmaceuticals' Common Equity (Quarter) stood at $434.0 million in 2022, then grew by 0.78% to $437.4 million in 2023, then fell by 22.91% to $337.2 million in 2024, then fell by 25.0% to $252.9 million in 2025.
- Its last three reported values are $252.9 million in Q3 2025, $274.5 million for Q2 2025, and $295.4 million during Q1 2025.